Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings Shenzhen YHLO Biotech Co., Ltd.: Strengths and Weaknesses

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Shenzhen YHLO Biotech Co., Ltd.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses: Shenzhen YHLO Biotech Co., Ltd.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • Low profitability weakens the company.
  • With an expected P/E ratio at 16.88 and 18.71 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

Shenzhen YHLO Biotech Co., Ltd. SectorChina

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

-

ROE

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

More ratings

Rating Valuation

Shenzhen YHLO Biotech Co., Ltd. SectorChina

Global Valuation

-

Enterprise value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

Shenzhen YHLO Biotech Co., Ltd. SectorChina

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Shenzhen YHLO Biotech Co., Ltd. SectorChina

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Shenzhen YHLO Biotech Co., Ltd. SectorChina

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
805M - -
12.59B
BBB
9.42B -
BB
- -
6.21B
BBB
5.54B
B
4.15B
BBB
4.18B - - - - -
3.73B
AA
1.95B -
A
- -
1.65B - - - - -
Average 5.02B
A
Weighted average by Cap.
A
  1. Stock Market
  2. Stocks
  3. 688575 Stock
  4. Ratings Shenzhen YHLO Biotech Co., Ltd.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW